Two New Compounds Could Reveal Hidden Drivers of Alzheimer's Disease

Vanderbilt researchers have created the first selective compound designed to inhibit TAOK-1, a poorly understood protein connected to Alzheimer's disease, and a second compound that activates the entire TAOK protein family, ScienceDaily reported on August 3. Together, the two compounds offer scientists an unexpected new tool for probing one of the most stubborn diseases in biomedicine.

Why TAOK-1 Matters

TAOK-1 is a kinase implicated in multiple neurodegenerative pathways, including tau phosphorylation and neuroinflammation. It has been studied for years but, until now, no one had a selective chemical probe for it. Most existing compounds either don't bind tightly enough or hit other kinases off-target. The Vanderbilt team designed a molecule that binds TAOK-1 selectively at low nanomolar concentrations.

"We finally have a tool that asks the right question," the team wrote.

What the Compounds Do

The inhibitor shuts down TAOK-1 activity in cells, allowing researchers to see what happens when the protein is removed. The activator does the opposite - it turns on the entire TAOK family, including the less-understood TAOK-2 and TAOK-3. Together, the two compounds let scientists map the entire TAOK signaling network in neurons for the first time.

What's Next

The Vanderbilt team is now collaborating with academic and industry partners to test the inhibitor in animal models of Alzheimer's. The activator is being used as a research tool across a network of academic labs. A small biotech has licensed the inhibitor for early-stage drug development, though no clinical trials are imminent. The work was published in the journal Nature Chemical Biology.